NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$33.82
-0.75 (-2.17 %)
(As of 09/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.36
$34.63
50-Day Range
$30.65
$34.78
52-Week Range
$30.12
$58.35
Volume204,050 shs
Average Volume222,496 shs
Market Capitalization$1.97 billion
P/E Ratio91.41
Dividend YieldN/A
Beta0.69
30 days | 90 days | 365 days | Advanced Chart
Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.


Xencor logo

About Xencor

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

564th out of 1,352 stocks

Pharmaceutical Preparations Industry

273rd out of 665 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

What stocks does MarketBeat like better than Xencor?

Wall Street analysts have given Xencor a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xencor wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.61) by $1.48. Xencor had a net margin of 13.17% and a trailing twelve-month return on equity of 3.97%.
View Xencor's earnings history
.

How has Xencor's stock been impacted by Coronavirus (COVID-19)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XNCR shares have increased by 20.3% and is now trading at $33.82.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XNCR?

6 Wall Street analysts have issued 1 year price objectives for Xencor's stock. Their forecasts range from $34.00 to $59.00. On average, they anticipate Xencor's stock price to reach $51.17 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Bassil I. Dahiyat, President, Chief Executive Officer & Director
  • John J. Kuch, Chief Financial Officer & Senior Vice President
  • John R. Desjarlais, Chief Scientific Officer & Senior VP-Research
  • Allen Yang, Chief Medical Officer & Senior Vice President
  • Celia Eckert, Secretary, General Counsel & Vice President

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.75%), FMR LLC (14.17%), Vanguard Group Inc. (10.85%), Price T Rowe Associates Inc. MD (10.05%), Primecap Management Co. CA (9.08%) and State Street Corp (4.47%). Company insiders that own Xencor stock include Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor
.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., FMR LLC, Squarepoint Ops LLC, California Public Employees Retirement System, SG Americas Securities LLC, Northern Trust Corp, and Legal & General Group Plc. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor
or view top insider-selling stocks.

Which institutional investors are buying Xencor stock?

XNCR stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Price T Rowe Associates Inc. MD, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Citadel Advisors LLC, Millennium Management LLC, Renaissance Technologies LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Xencor
or or view top insider-buying stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $33.82.

How much money does Xencor make?

Xencor has a market capitalization of $1.97 billion and generates $122.69 million in revenue each year. The biopharmaceutical company earns $-69,330,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 202 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

Where are Xencor's headquarters?

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.